AGIOS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $60.40 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2015-02-24
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2014-12-31 was $15.60M, a 333.33% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2014-09-30 was $10.00M, a 4900.00% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2014-06-30 was $10.70M, a 2575.00% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2014-03-31 was $24.10M, a 24000.00% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2014 was $60.40M, a 1338.10% increase from fiscal 2013.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2013 was $4.20M, a 425.00% increase from fiscal 2012.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2012 was $800.00K, a 700.00% increase from fiscal 2011.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2011 was $100.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2014-12-31 | $15.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $25.60M derived: sum of 2 quarters · filed 2015-02-24 | $36.30M derived: sum of 3 quarters · filed 2015-02-24 | $60.40M 10-K · filed 2015-02-24 |
| 2014-09-30 | $10.00M 10-Q · filed 2014-11-07 | $20.70M derived: sum of 2 quarters · filed 2014-11-07 | $44.80M 10-Q · filed 2014-11-07 | $48.40M derived: sum of 4 quarters · filed 2015-02-24 |
| 2014-06-30 | $10.70M 10-Q · filed 2014-08-07 | $34.80M 10-Q · filed 2014-08-07 | $38.40M derived: sum of 3 quarters · filed 2015-02-24 | $38.60M derived: sum of 4 quarters · filed 2015-02-24 |
| 2014-03-31 | $24.10M 10-Q · filed 2014-05-09 | $27.70M derived: sum of 2 quarters · filed 2015-02-24 | $27.90M derived: sum of 3 quarters · filed 2015-02-24 | $28.30M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $3.80M derived: sum of 2 quarters · filed 2015-02-24 | $4.20M derived: sum of 3 quarters · filed 2015-02-24 | $4.20M 10-K · filed 2015-02-24 |
| 2013-09-30 | $200.00K 10-Q · filed 2014-11-07 | $600.00K derived: sum of 2 quarters · filed 2014-11-07 | $600.00K 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $400.00K 10-Q · filed 2014-08-07 | $400.00K 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $100.00K 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $800.00K 10-K · filed 2015-02-24 | |||
| 2011-12-31 | $100.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |